2012-11-14T14:31:11-06:00 2011-12-31 521480805 CHACONAS & WILSON PC 2100 PENNSYLVANIA AVENUE NW 580 WASHINGTON DC 20037 990 2011-01-01 237376197 HEREDITARY DISEASE FOUNDATION HERE 2129280420 3960 BROADWAY 6TH FLOOR NEW YORK NY 10032 NANCY WEXLER 2129280420 2012-11-14 1 MOLLIE LAMBERT P01336155 2024298890 2011 2016-02-24 21:20:13Z NANCY WEXLER 3960 BROADWAY NEW YORK NY 10032 4447435 0 X WWW.HDFOUNDATION.ORG X 1968 CA ALL OF THE RESEARCH FOCUSES ON DISCOVERING NEW TREATMENTS AND CURES FOR HUNTINGTON'S DISEASE AND RELATED DISORDERS. THE STARTING POINT FOR MOST OF THE RESEARCH HAS BEEN THE QUESTION OF HOW THE EXPANSION OF A POLYGLUTAMINE TRACT IN A PROTEIN CALLED HUNTINGTIN CAN LEAD TO NEURODEGENERATIVE DISEASES. 17 10 5 0 0 0 2214255 661521 0 0 363242 264612 0 0 2577497 926133 669122 680948 0 0 518550 551499 0 0 34006 930538 860414 2118210 2092861 459287 -1166728 10852807 9436673 471177 596220 10381630 8840453 X ALL OF THE RESEARCH FOCUSES ON DISCOVERING NEW TREATMENTS AND CURES FOR HUNTINGTON'S DISEASE AND RELATED DISORDERS. THE STARTING POINT FOR MOST OF THE RESEARCH HAS BEEN THE QUESTION OF HOW THE EXPANSION OF A POLYGLUTAMINE TRACT IN A PROTEIN CALLED HUNTINGTIN CAN LEAD TO NEURODEGENERATIVE DISEASES. 0 0 1789598 680948 THE STARTING POINT FOR MOST OF THE RESEARCH HAS BEEN THE QUESTION OF HOW THE EXPANSION OF A POLYGLUTAMINE TRACT IN A PROTEIN CALLED HUNTINGTIN CAN LEAD TO NEURODEGENERATIVE DISEASE. MUCH OF THE RESEARCH FOCUS HAS BEEN ON ESSAYS THAT WILL ALLOW HIGH THROUGH-PUT SCREENING OF MOLECULES THAT CAN BE TURNED INTO MEDICINES. 1789598 1 1 0 0 0 0 0 0 0 1 1 1 0 0 1 1 1 0 0 0 1 0 1 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 0 0 5 1 0 0 0 0 0 1 1 0 0 0 0 X 17 10 1 0 0 0 0 0 0 1 1 0 0 0 1 0 0 1 0 1 1 0 CA NY X KAREN DEAN 2129280420 3960 BROADWAY 6TH FLOOR NEW YORK NY 10032 NANCY WEXLER PHD 35.00 X X 0 0 0 FRANK GEHRY 1.00 X 0 0 0 BERTA GEHRY 2.00 X 0 0 0 ALICE WEXLER PHD 2.00 X 0 0 0 GERALD ARONSON MD 1.00 X 0 0 0 ROBI BLUMENSTEIN 1.00 X 0 0 0 BRUCE DONALDSON 1.00 X 0 0 0 JODIE EVANS 1.00 X 0 0 0 SANDY FOX 1.00 X 0 0 0 DAVID GERSTENHABER 1.00 X 0 0 0 KELLY POSNER GERSTENHABER PHD 1.00 X 0 0 0 ARTHUR GOLDING MD 1.00 X 0 0 0 JONATHAN GUEST 1.00 X 0 0 0 DAVID HOUSMAN PHD 1.00 X 0 0 0 JONATHAN MATZ 1.00 X 0 0 0 HERBERT PARDES MD 2.00 X 0 0 0 ANNE B YOUNG MD PHD 1.00 X 0 0 0 CARL JOHNSON 40.00 X 190000 0 15723 KAREN DEAN 40.00 X 101750 0 15589 291750 0 31312 2 0 1 0 0 661521 661521 308662 308662 3477252 3521302 -44050 -44050 -44050 926133 -44050 0 308662 554547 554547 126401 126401 205723 205723 253149 110580 128765 13804 63551 28189 34577 785 29076 18736 9577 763 905 905 21472 14386 6227 859 57756 57756 224737 217103 7184 450 168314 149761 16807 1746 177947 119294 53196 5457 34708 33542 1097 69 133947 133947 14858 9293 5244 321 11866 6545 4213 1108 SPECIAL EVENT 8644 8644 DUES AND SUBSCRIPTIONS 3665 3665 TAXES AND LICENSES 1595 130 1465 2092861 1789598 269257 34006 258618 12004 329811 249209 672 33333 646982 332590 321073 314392 9683938 6198978 2373235 258695 255522 10852807 9436673 43779 111330 418650 469550 8748 15340 471177 596220 X 2228813 929806 8152817 7910647 10381630 8840453 10852807 9436673 X -1166728 -374449 X X 0 1 0 X 0 X 1960654 2096774 560667 2214255 661521 7493871 1960654 2096774 560667 2214255 661521 7493871 2709442 4784429 480617 401018 289511 279992 308662 1759800 1000 1000 9254671 0.51700 0.53360 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 8152817 173820 -173007 242983 7910647 7676747 676070 200000 8152817 6576189 1454238 353680 7676747 9256971 -2224126 456656 6576189 1.00000 0 0 401737 98188 303549 200505 190063 10442 44740 44339 401 314392 FHLMC 4.625% 10/25/12 518005 F FHLMC 4.125% 09/27/13 638526 F FNMA 5.25% 09/15/16 593545 F FNMA 5% 05/11/17 623159 F 2373235 ACCRUED VACATION 15340 15340 926133 2092861 -1166728 -374449 -374449 -1541177 493928 -374449 -374449 868377 57756 57756 926133 2035105 0 2035105 57756 57756 2092861 DESCRIPTION OF INTENDED USE OF ENDOWMENT FUNDS: PART V, LINE 4: ERADICATE GENETIC ILLNESS DESCRIPTION OF UNCERTAIN TAX POSITIONS UNDER FIN 48: PART X: THE FOUNDATION HAS ADOPTED FASB ACCOUNTING STANDARDS CODIFICATION 740-10, INCOME TAXES, WHICH PRESCRIBES MEASUREMENT AND DISCLOSURE REQUIRMENTS FOR CURRENT AND DEFERRED INCOME TAX PROVISIONS. THE INTERPRETAION PROVIDES FOR A CONSISTENT APPROACH IN IDENTIFYING AND REPORTING UNCERTAIN TAX POSITIONS. IT IS MANAGEMENT'S BELIEF THAT THE FOUNDATION DOES NOT HOLD ANY UNCERTAIN TAX POSITIONS. PART XII, LINE 2D - OTHER ADJUSTMENTS: NET UNREALIZED LOSSES ON INVESTMENTS -374,449. 1 EUROPE 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION GRANTS TO HELP IDENTIFY ROUTES TO THE DEVELOPMENT OF CURES AND TREATMENTS FOR HUNTINGTON'S DISEASE AND OTHER SIMILAR HEREDITARY DISORDERS. 126401 0 0 0 0 0 0 126401 0 126401 HEREDITARY DISEASE FOUNDATION GRANTS ARE HELPING IDENTIFY ROUTES TO THE DEVELOPMENT OF CURES AND TREATMENTS FOR HUNTINGTON'S DISEASE AND OTHER SIMILAR HEREDITARY DISORDERS. EUROPE 2 126401 CHECK N/A N/A 0 0 0 0 0 0 PROCEDURE FOR MONITORING GRANTS OUTSIDE THE U.S.: SCHEDULE F, PART I, LINE 2: THE GRANT RECIPIENTS ARE REQUIRED TO SUBMIT PROGRESS REPORTS IN ORDER TO RECEIVE ADDITIONAL FUNDING. THE DIRECTOR OF SCIENCE REVIEWS THE PROGRESS REPORTS AND AUTHORIZES THE ADDITIONAL FUNDING. AT THE END OF THE GRANT PERIOD THE GRANT RECIPIENTS SUBMIT A FINAL REPORT. 1 HEREDITARY DISEASE FOUNDATION GRANTS ARE HELPING IDENTIFY ROUTES TO THE DEVELOPMENT OF CURES AND TREATMENTS FOR HUNTINGTON'S DISEASE AND OTHER SIMILAR HEREDITARY DISORDERS. 14 554547 N/A PROCEDURE FOR MONITORING GRANTS IN THE U.S.: PART I, LINE 2: SCHEDULE I, PART I, LINE 2: THE GRANT RECIPIENTS ARE REQUIRED TO SUBMIT PROGRESS REPORTS IN ORDER TO RECEIVE ADDITIONAL FUNDING. THE DIRECTOR OF SCIENCE REVIEWS THE PROGRESS REPORTS AND AUTHORIZES THE ADDITIONAL FUNDING. AT THE END OF THE GRANT PERIOD THE GRANT RECIPIENTS SUBMIT A FINAL REPORT. X 0 0 0 0 0 0 0 0 0 CARL JOHNSON 190000 0 0 0 0 0 0 0 15723 0 205723 0 0 0 X 12 35026 FMV DATE OF DONATION 0 0 0 FORM 990, PART VI, SECTION A, LINE 2 THE PRESIDENT OF THE BOARD OF DIRECTORS AND THE SECRETARY ARE SISTERS. THE TREASURER AND THE VICE-PRESIDENT OF THE BOARD OF DIRECTORS ARE HUSBAND AND WIFE. TWO OTHER BOARD MEMBERS ARE ALSO HUSBAND AND WIFE. JONATHAN MATZ IS THE FOUNDATION'S INVESTMENT ADVISOR AT GOLDMAN SACHS. GOLDMAN SACHS RECEIVED $57,756 IN INVESTMENT FEES. FORM 990, PART VI, SECTION B, LINE 11 THE BOARD OF DIRECTORS HAS DESIGNATED THE PRESIDENT AND/OR THE SECRETARY OF THE BOARD TO REVIEW THE FORM 990 BEFORE IT IS FILED. FORM 990, PART VI, SECTION B, LINE 15 THE DIRECTOR OF SCIENCE'S SALARY WAS DETERMINED THROUGH A SIGNED AGREEMENT/CONTRACT THAT WAS APPROVED BY THE BOARD OF DIRECTORS. FORM 990, PART VI, SECTION C, LINE 18 THE FOUNDATION'S FORM 990 AND FORM 1023 ARE AVAILABLE UPON REQUEST. FORM 990, PART VI, SECTION C, LINE 19 THE DOCUMENTS ARE AVAILABLE UPON WRITTEN REQUEST. CHANGES IN NET ASSETS OR FUND BALANCES: FORM 990, PART XI, LINE 5: NET UNREALIZED LOSSES ON INVESTMENTS: -374,449. FORM 990 PART XII LINE 2C; THE PRESIDENT OF THE FOUNDATION AND ONE OF THE BOARD OF DIRECTORS ASSUMES RESPONSIBILITY FOR OVERSIGHT OF THE AUDIT. THIS PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR.